Interim Analysis of the Randomized Phase 1b/3 Study Evaluating the Safety and Efficacy of Tazemetostat Plus Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma

被引：5

作者：

Batlevi, Connie Lee ^{[1
]}

Park, Steven I. ^{[2
]}

Nastoupil, Loretta ^{[3
]}

Phillips, Tycel ^{[4
]}

Amengual, Jennifer E. ^{[5
]}

Andorsky, David ^{[6
]}

Campbell, Philip ^{[7
]}

McKay, Pamela ^{[8
]}

Pagel, John M. ^{[9
]}

Leonard, John P. ^{[10
]}

Yang, Jay ^{[11
]}

O'Connor, Heather ^{[11
]}

Hamlett, Anthony ^{[11
]}

Adib, Deyaa ^{[11
]}

Morschhauser, Franck ^{[12
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY USA

[2] Levine Canc Inst, Dept Hematol Oncol & Blood Disorders, Charlotte, NC USA

[3] MD Anderson Canc Ctr, Houston, TX USA

[4] Univ Michigan, Ann Arbor, MI USA

[5] Columbia Univ, Irving Med Ctr, New York, NY USA

[6] Rocky Mt Canc Ctr, Boulder, CO USA

[7] Univ Hosp Geelong, Barwon Hlth, Geelong, Vic, Australia

[8] Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland

[9] Swedish Canc Inst, Ctr Blood Disorders & Stem Cell Transplantat, Seattle, WA USA

[10] Weill Cornell Med, New York, NY USA

[11] Epizyme Inc, Cambridge, MA USA

[12] Univ Lille, CHU Lille, EA 7365 GRITA Grp Rech Formes Injectables & Tec, F-59000 Lille, France

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-148199

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2207

引用

页数：6

共 50 条

[41] Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study [J].

Salles, Gilles ;

Schuster, Stephen J. ;

de Vos, Sven ;

Wagner-Johnston, Nina D. ;

Viardot, Andreas ;

Blum, Kristie A. ;

Flowers, Christopher R. ;

Jurczak, Wojciech J. ;

Flinn, Ian W. ;

Kahl, Brad S. ;

Martin, Peter ;

Kim, Yeonhee ;

Shreay, Sanatan ;

Will, Matthias ;

Sorensen, Bess ;

Breuleux, Madlaina ;

Zinzani, Pier Luigi ;

Gopal, Ajay K. .

HAEMATOLOGICA, 2017, 102 (04) :E156-E159

[42] Phase 1b study to investigate the safety and tolerability of idelalisib in Japanese patients with relapsed/refractory follicular lymphoma and chronic lymphocytic leukemia [J].

Fukuhara, Noriko ;

Kinoshita, Tomohiro ;

Yamamoto, Kazuhito ;

Nagai, Hirokazu ;

Izutsu, Koji ;

Yamamoto, Go ;

Bhargava, Pankaj ;

Rajakumaraswamy, Nishan ;

Humeniuk, Rita ;

Mathias, Anita ;

Xing, Guan ;

Fukui, Masato ;

Tobinai, Kensei .

JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2020, 50 (12) :1395-1402

[43] Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study [J].

Abrisqueta, Pau ;

Gonzalez-Barca, Eva ;

Panizo, Carlos ;

Perez, Jose Maria Arguinano ;

Miall, Fiona ;

Bastos-Oreiro, Mariana ;

Triguero, Ana ;

Banerjee, Lalita ;

Mcmillan, Andrew ;

Seymour, Erlene ;

Hirata, Jamie ;

de Guzman, Jayson ;

Sharma, Sunil ;

Jin, Hyun Yong ;

Musick, Lisa ;

Diefenbach, Catherine .

LANCET HAEMATOLOGY, 2024, 11 (02) :e136-e146

[44] POLATUZUMAB VEDOTIN PLUS BENDAMUSTINE AND RITUXIMAB OR OBINUTUZUMAB IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA OR DIFFUSE LARGE B-CELL LYMPHOMA: UPDATED RESULTS OF A PHASE 1B/2 STUDY [J].

Matasar, M. ;

Herrera, A. F. ;

Kamdar, M. ;

Mehta, A. ;

Assouline, S. ;

Fleury, I. ;

Kim, T. M. ;

Kim, W. S. ;

Bosch, F. ;

Radford, J. ;

Flowers, C. R. ;

Bu, L. ;

Hong, W. -J. ;

Sehn, L. H. .

HAEMATOLOGICA, 2017, 102 :173-173

[45] inMIND: A Phase 3 Study of Tafasitamab plus Lenalidomide Add-On to Rituximab vs Placebo plus Lenalidomide Add-On to Rituximab for Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Marginal Zone Lymphoma (MZL) [J].

Sehn, Laurie H. ;

Scholz, Christian W. ;

Luminari, Stefano ;

Salar, Antonio ;

Wahlin, Bjorn E. ;

Gopal, Ajay K. ;

Bonnet, Christophe ;

Trneny, Marek ;

Paneesha, Shankara ;

Manzke, Oliver ;

Seguy, Francis ;

Li, Di ;

Huebel, Kai .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 :S402-S402

[46] Phase 3, Randomized, Open-Label Study of Epcoritamab Plus Lenalidomide Compared with Rituximab Plus Gemcitabine and Oxaliplatin in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma [J].

Ozcan, Muhit ;

Kim, Won Seog ;

Zhang, Huilai ;

Bouzani, Maria ;

Nagy, Zsolt ;

Chuah, Hun ;

Salles, Gilles ;

Jeng, Edwin E. ;

Huang, Jiangeng ;

Sacchi, Mariana ;

Jiang, Yajian ;

Minson, Adrian .

BLOOD, 2024, 144 :45021-45022

[47] Safety and Efficacy of Rituximab Plus Bendamustine in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Patients [J].

Arcari, Annalisa ;

Chiappella, Annalisa ;

Valenti, Vanessa ;

Zanlari, Luca ;

Tani, Monica ;

Marasca, Roberto ;

Cabras, Maria Giuseppina ;

Spina, Michele ;

Santagostino, Alberto ;

Ilariucci, Fiorella ;

Carli, Giuseppe ;

Musto, Pellegrino ;

Savini, Paolo ;

Marino, Dario ;

Ghio, Francesco ;

Gentile, Massimo ;

Cox, Maria Christina ;

Della Seta, Roberta ;

Vallisa, Daniele .

BLOOD, 2014, 124 (21)

[48] Phase 1b/2 Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory and Untreated Mantle Cell Lymphoma: Safety, Efficacy, and Molecular Analysis [J].

Melani, Christopher ;

Lakhotia, Rahul ;

Pittaluga, Stefania ;

Miljkovic, Milos D. ;

Phelan, James D. ;

Muppidi, Jagan R. ;

Thomas, Craig J. ;

Ceribelli, Michele ;

Juanitez, Anna Marie ;

Pradhan, Amynah ;

Hillsman, Amy ;

Steinberg, Seth M. ;

Jaffe, Elaine S. ;

Roschewski, Mark ;

Staudt, Louis M. ;

Wilson, Wyndham H. .

BLOOD, 2021, 138

[49] A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma [J].

Reid W. Merryman ;

Robert A. Redd ;

Arnold S. Freedman ;

Inhye E. Ahn ;

Jennifer R. Brown ;

Jennifer L. Crombie ;

Matthew S. Davids ;

David C. Fisher ;

Eric D. Jacobsen ;

Austin I. Kim ;

Ann S. LaCasce ;

Samuel Ng ;

Oreofe O. Odejide ;

Erin M. Parry ;

Iris Isufi ;

Justin Kline ;

Jonathon B. Cohen ;

Neha Mehta-Shah ;

Nancy L. Bartlett ;

Matthew Mei ;

Thomas M. Kuntz ;

Jacquelyn Wolff ;

Scott J. Rodig ;

Philippe Armand ;

Caron A. Jacobson .

Annals of Hematology, 2024, 103 :185-198

[50] A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma [J].

Merryman, Reid W. ;

Redd, Robert A. ;

Freedman, Arnold S. ;

Ahn, Inhye E. ;

Brown, Jennifer R. ;

Crombie, Jennifer L. ;

Davids, Matthew S. ;

Fisher, David C. ;

Jacobsen, Eric D. ;

Kim, Austin I. ;

LaCasce, Ann S. ;

Ng, Samuel ;

Odejide, Oreofe O. ;

Parry, Erin M. ;

Isufi, Iris ;

Kline, Justin ;

Cohen, Jonathon B. ;

Mehta-Shah, Neha ;

Bartlett, Nancy L. ;

Mei, Matthew ;

Kuntz, Thomas M. ;

Wolff, Jacquelyn ;

Rodig, Scott J. ;

Armand, Philippe ;

Jacobson, Caron A. .

ANNALS OF HEMATOLOGY, 2024, 103 (01) :185-198

← 1 2 3 4 5 →